111 related articles for article (PubMed ID: 385948)
1. Clinical trials in vaccination with leukemia associated antigens in acute myelogenous leukemia.
Alsabti EA; Taleb AM; Raji HM; Kalil OZ; Saleh KA
Jpn J Exp Med; 1979 Jun; 49(3):157-68. PubMed ID: 385948
[TBL] [Abstract][Full Text] [Related]
2. The effect of immunotherapy on survival of patients with acute myelogenous leukaemia after relapse.
Powles R; Toy JL
Haematologia (Budap); 1976; 10(1):5-9. PubMed ID: 1070466
[TBL] [Abstract][Full Text] [Related]
3. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
4. The role of immunotherapy in acute myelogenous leukemia.
Foon KA; Smalley RV; Riggs CW; Gale RP
Arch Intern Med; 1983 Sep; 143(9):1726-31. PubMed ID: 6577818
[TBL] [Abstract][Full Text] [Related]
5. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
Hewlett JS; Chen T; Balcerzak SP; Gutterman JU; Costanzi JJ; Amare M
Arch Intern Med; 1985 Jun; 145(6):1006-12. PubMed ID: 3890786
[TBL] [Abstract][Full Text] [Related]
6. Anti-leprosy protective vaccination of rhesus monkeys with BCG or BCG plus heat-killed Mycobacterium leprae: lepromin skin test results.
Gormus BJ; Baskin GB; Xu K; Ratterree MS; Mack PA; Bohm RP; Meyers WM; Walsh GP
Lepr Rev; 2002 Sep; 73(3):254-61. PubMed ID: 12449891
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy of acute myelogenous leukemia (AML) in adults with the Nocardia rubra cell wall skeleton].
Ohno R; Nakamura H; Kodera Y; Masaoka T; Yamada K
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1264-9. PubMed ID: 3524463
[TBL] [Abstract][Full Text] [Related]
8. A clinical trial of cell-wall skeleton of BCG in chemoimmunotherapy of acute leukemia.
Ohino R; Ueda R; Imai Kato Y; Watanabe E; Morishima Y; Yokomaku S; Kobayashi M; Takeyama H; Ezaki K; Kawashima K; Hirano M; Ohara K; Kosaki T; Yoshikawa S; Yamada K
Gan; 1978 Apr; 69(2):179-86. PubMed ID: 355038
[TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
Greiner J; Döhner H; Schmitt M
Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy.
Granatek CH; Ezaki K; Hersh EM; Keating MJ; Rasmussen S
Cancer; 1981 Jan; 47(2):272-9. PubMed ID: 7006793
[TBL] [Abstract][Full Text] [Related]
11. Sensitization potential and reactogenicity of BCG with and without various doses of killed Mycobacterium leprae.
Gupte MD; Anantharaman DS; De Britto RL; Vallishayee RS; Nagaraju B; Kannan S; Sengupta U
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):340-52. PubMed ID: 1474275
[TBL] [Abstract][Full Text] [Related]
12. Antileprosy protective vaccination of sooty mangabey monkeys with BCG or BCG plus heat-killed Mycobacterium leprae: immunologic observations.
Gormus BJ; Baskin GB; Xu K; Ratterree MS; Martin LN; Mack PA; Bohm RP; Meyers WM; Walsh GP
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):434-43. PubMed ID: 11332286
[TBL] [Abstract][Full Text] [Related]
13. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells.
Greiner J; Bullinger L; Guinn BA; Döhner H; Schmitt M
Clin Cancer Res; 2008 Nov; 14(22):7161-6. PubMed ID: 19010831
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
15. [The frequency profile of tuberculin skin testing among students in nursing school].
Fujino T; Abe Y; Miyata A; Suzuki K
Kekkaku; 1999 Jun; 74(6):493-7. PubMed ID: 10423960
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of chronic myelocytic leukemia: effects of different vaccination schedules.
Sokal JE; Aungst CW; Snyderman M; Gomez G
Ann N Y Acad Sci; 1976; 277(00):367-83. PubMed ID: 1069556
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
19. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in the management of myelogenous leukemia.
Fairley GH
Arch Intern Med; 1976 Dec; 136(12):1406-12. PubMed ID: 793553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
